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GENETIC MODIFICATION OF THE HUMAN GERM LINE: THE REASONS WHY 
THIS PROJECT HAS FADED 
 
CHANGER LES GENES? UN PROJET QUI N'EST PLUS PRIORITAIRE 
 
 
Résumé: 
La modification ciblée de la lignée germinale (et donc de l‘espèce humaine) est restée un 
objectif distant mais raisonnable, depuis l‘émergence de la génétique (et même avant) jusqu‘à 
ces dernières années. J‘ai choisi trois temps pour étudier les évolutions historiques de ce 
projet – dans les années 1930, au sommet du mouvement eugéniste, autour de 1974 quand la 
biologie moléculaire triomphait, et aujourd‘hui – et j‘ai sélectionné trois critères pour estimer 
la faisabilité d‘un tel projet – l‘état des connaissances scientifiques, l‘existence de techniques 
adaptées, et les demandes de la société. Bien que les techniques longtemps espérées pour 
modifier la lignée germinale soient aujourd‘hui disponibles, je montrerai que la plupart des 
attentes qui soutenaient ce projet ont disparu, ou sont considérées comme pouvant être 
atteintes par des stratégies totalement différentes.  
 
 
Abstract: 
Modification of the human germ line has remained a distant but valuable objective for most 
biologists since the emergence of genetics (and even before). To study the historical 
transformations of this project, I have selected three periods—the 1930s, at the pinnacle of 
eugenics, around 1974 when molecular biology triumphed, and today—and have adopted 
three criteria to estimate the feasibility of this project: the state of scientific knowledge, the 
existence of suitable tools, and societal demands. Although the long-awaited techniques to 
modify the germ line are now available, I will show that most of the expectations behind this 
project have disappeared, or are considered as being reachable by highly different strategies. 
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*** 
 
The Colloquium ―Biologie et devenir de l‘homme‖ was organized in Paris in 1974, at a 
time when the new discipline of molecular biology had a very high profile. In the preceding 
years, the chemical nature and structure of the genes had been unveiled, the origin of 
mutations understood, and the precise relation between genes and proteins (the genetic code) 
discovered. Molecular biology had rapidly acquired a dominant position within scientific 
institutions: the recent appointment of Jacques Monod to Director of the Pasteur Institute was 
a sign of this newly acquired power. In addition, molecular biology was on the eve of a new 
revolution—the rise of genetic engineering. The projects were already there, and the first 
steps had been accomplished in US laboratories. However, these early achievements had been 
acknowledged by a very small number of French biologists. 
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The objective of the 1974 Colloquium was to discuss the new powers of biology, and the 
new duties of biologists. Within this framework, I have decided to examine how the project to 
modify the human germ line genetically was reconsidered after the rise of molecular biology, 
and what it has become forty years later, with the huge amount of biological information 
acquired since the beginnings of molecular biology. This project has a very long historical 
background, even if the name given to it changed with the state of knowledge, and the tools at 
its disposal. What would in the past have been called ―transformation of the human species‖ is 
now considered as ―genetic enhancement‖, or more neutrally as ―genome editing‖. Despite 
these changes in vocabulary, the objective has remained similar, with its two projects—the 
correction of genetic defects and the enhancement of human genetic abilities. I will compare 
these two projects and the contrasting attitudes towards them, in the 1970s and today. I 
needed a point of reference, which I have chosen as the 1930s, at the pinnacle of eugenics. In 
the first part, I will present the criteria that I have selected to estimate the feasibility of these 
projects at a given time. Quite surprisingly, I will provide evidence for an inverse relation 
between the extent of knowledge and the availability of techniques permitting the 
modification of the genome, and the priority accorded to these projects. Today, the 
technologies are there, but the motivation has disappeared!  
 
CRITERIA TO ESTIMATE THE FEASIBILITY OF THESE PROJECTS 
Three criteria must be fulfilled for such projects to be developed. The first is a sufficient 
state of knowledge. The second is the availability of tools permitting their realization. And the 
third is that such projects have to be considered as valuable, a priority not only for specialists, 
but for a large fraction of society. These criteria are obviously of relative value. Scientific 
knowledge can be considered sufficient at a given time, and only later shown to have been 
insufficient to support the projects that were proposed. The social consensus is never perfect 
and is particularly difficult to gauge in authoritarian societies. The notion of ―scientific 
knowledge‖ is not as simple as might be thought at first glance: to appreciate the 
consequences of a genetic modification of the germ line, the skills of molecular biologists are 
not sufficient: population geneticists and evolutionary biologists are needed to estimate the 
long-term consequences of these modifications. 
 
PROJECTS IN THE 1930S 
The idea that it was necessary to control (and to improve) human reproduction is not new. 
Plato, and Cabanis at the beginning of the 19
th
 century, were advocates. After the acceptance 
of Darwinian evolutionary theory, this ambition dramatically evolved into the idea of 
replacing the action of natural selection, which had disappeared in human societies because of 
the development of social and medical care, by artificial selection. It was deemed necessary 
both to improve the reproduction of the best and to prevent the reproduction of individuals 
likely to transmit their physical and mental deficiencies to their progeny.  
Eugenic methods of forced sterilization were not unanimously accepted in the first 
decades of the 20
th
 century, but there was a wide consensus on the necessity and possibility to 
improve the human species. The talk given by the physical chemist Jean Perrin at the 
inauguration of the newly constructed Institute of Physical-Chemical Biology (IBPC) in Paris 
in 1927 bears witness to these expectations: ―The issue is to modify, maybe to a prodigious 
degree, the type of equilibrium, the organs, the hereditary basis of organisms. This search for 
an experimental transformation of species will play for the biologist a role analogous to that 
played for the chemist for centuries by the transmutation of elements... This research may 
lead us, must lead us, to transform current human beings, unchanged for millennia, into higher 
and higher beings, richer in sensations, feelings, and thoughts, and more generally richer in 
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what will correspond for consciousness to a wider and more complex development of the 
brain‖ (1). 
The stimulating role of physics in future developments in biology is obvious in this 
quotation: the transformation of elements has become feasible for the chemist, as the 
transformation of species will be for the biologist in the near future. Experimental 
transformism refers to the neo-Lamarckian tradition dominant among French biologists (2), 
according to which organisms can be directly modified through changes in the environment. 
In the following years, under the impetus given by population geneticists, the Modern 
Synthesis between genetics and Darwinism was elaborated by the evolutionary biologists 
Julian Huxley, Ernst Mayr, Theodosius Dobzhansky, George Simpson and others. Most of the 
founders of the Modern Synthesis accepted the idea that human beings were at the top of 
evolution, the first to have had access to its rules. For this reason, they were now in charge of 
evolution, of the future transformations of organisms and human beings (3). Even George 
Simpson, the most committed of evolutionary biologists in the fight against finalism, 
nevertheless admitted that ―the fact that man knows that he evolves entails the possibility that 
he can do something to influence his own biological destiny‖ (4). 
By using our criterion of feasibility, it is obvious that these projects were beyond reach. 
The experimental transformism never worked, i.e. changes in the environment never directly 
produced stable modifications of the progeny. The models used by eugenicists to develop 
their projects were rapidly shown to be not only simplistic, but also scientifically incorrect. 
Feeble-mindedness, one of the major incentives for forced sterilization, was not due to one 
unique recessive mutation as initially proposed by H. Goddard (5). And if most of the defects 
result from recessive mutations, forced sterilization will have a limited effect since it does not 
prevent the transmission of ―bad‖ copies of the genes through generations. 
The consensus in favour of a genetic modification was initially strong, but it progressively 
faded because of the way the eugenic measures had been applied in the US, and later in 
Germany. As was argued by Thomas Morgan as early as 1934 in his Nobel lecture, there are 
other more human ways to address these problems through medicine (6). 
 
PROJECTS AT THE TIME OF THE PARIS CONFERENCE 
Molecular biologists had contrasting attitudes towards the projects of gene modification 
burgeoning in the 1960s and 1970s. Some were enthusiastic. Such was the case of Rollin 
Hotchkiss, a specialist in bacterial transformation: ―The wealthy and other royal families as 
always can even hope to purchase special advantage, such as determinants of musical ability, 
linkage groups providing skill in political oratory – or will they prefer skill in such 
gentlemanly pursuits as polo, or (somewhat less expensive) single factors enabling one to ride 
graceful and sure on an appropriately well-bred horse?‖ (7, p.199) Edward Tatum, the 
discoverer with George Beadle of the one gene–one enzyme relation, with Joshua Lederberg 
of sexuality in bacteria, was also convinced that with progress in our understanding of 
functioning and regulation of gene activity, it will be possible ―to exclude structural or 
metabolic errors in the developing organism but also to produce better organisms‖ (8). 
Bernard Davis was much more cautious in his ―prospects for genetic intervention in man‖, 
pointing to the difficulties stemming from the polygenic control of most human traits (9). 
Jacques Monod was even more pessimistic, considering that the complexity of the genomes of 
higher organisms prevented their modification, maybe forever (10).  
This absence of consensus among scientists reflected the particular situation that prevailed 
at the end of the 1960s, the contrast between the rapid discovery of the major principles 
guiding gene action in the preceding period and the complete absence of suitable tools for the 
isolation and characterization of the genes present in complex organisms. These tools were 
developed in the 1970s and by the 1980s were widely used in labs.  
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But there was also no social consensus on the need for such projects. Eugenics has now 
become a frightening word. Rollin Hotchkiss felt constrained to give credit to the altruism of 
the exponents of eugenics since the time of Galton – something that has been far from 
obvious (7, p.197). In the 1960s, in relation to the war in Vietnam, there was a generalized 
lack of confidence in science and technology. 
 
FROM THE 1970S TO TODAY 
In the last forty years, knowledge of genes and of the way they contribute to the 
construction of organisms and the realization of their functions has progressed dramatically. It 
has become possible, at least in the most favourable cases, to describe fully the causal chain 
that relates the product of a gene to the complex functions in the elaboration of which it 
participates; and to explain, in the case of mutations, the functional modification from the 
alteration of the gene.  
In parallel, Bernard Davis‘s anticipations have been fully confirmed: in most cases, there 
is no simple relation between a gene product and a function of the organism. Gene products 
cooperate in the formation of complex systems. In addition, the actions of genes cannot be 
understood without a precise description of the hierarchy of the structural levels forming an 
organism.  
What is most remarkable is the technological progress leading to the replacement at will 
of a gene in a genome by a different, modified version of the gene. As I have mentioned, the 
first step was the development of genetic engineering in the 1970s. This opened the door to 
animal and plant transgenesis, and to the first attempts at gene therapy. The main problem 
was that the position of gene insertion was uncontrolled. It remained impossible to replace a 
non-functional copy of a gene by a functional one; what was possible was simply to add to the 
genome a functional copy of the non-functional gene. The insertion might occur close to an 
oncogene or in a tumour-suppressor gene, facilitating the emergence of tumour cells. This 
occurred in the first attempts at gene therapy in France at the end of the 1990s in immune 
deficient babies (the so-called ―bubble babies‖ forced to live in a bubble protecting them from 
infection) (11). 
The only way to target a precise site in the genome was to insert the gene by homologous 
recombination. This strategy led at the end of the 1980s to the development of the knockout 
technology permitting the specific inactivation of a gene. The result was achieved not by an 
increase in the level of homologous recombination, but by the selection of the rare embryonic 
stem cells in which homologous recombination had occurred (12). These cells were injected 
into a blastocyst and transgenic animals were obtained at the next generation.  
This strategy could obviously not be used for modification of the human germ line. 
Different methods to increase the proportion of homologous recombination were tried, with 
results insufficient to permit any application to humans. The breakthrough occurred a few 
years ago with the adaptation to animals of a system used by bacteria to protect themselves 
against bacteriophages and foreign plasmids – the CRISPR-Cas system (13). In this system, 
the action of a nuclease is targeted towards a specific position in the genome by a guiding 
RNA, in presence of a template for homologous recombination.  
The efficiency is now sufficient to permit the correction of a genetic disease such as 
muscular dystrophy in mice by injection of the three components at the one-cell stage, after 
fertilization. The percentage of homologous recombination is not yet 100%, but already 
sufficient to correct the disease (14). It is a completely new result that opens the door to 
precise editing of the genome.  
A second line of research reached the point in its development where a modification in the 
human germ line seemed not only desirable, but also achievable. The first steps were done by 
biologists looking for a way to palliate alterations of the cytoplasm in the egg (15). They 
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showed that the injection of cytoplasmic extracts from normal individuals could correct the 
cytoplasmic abnormalities. It was hypothesized that these abnormalities probably originated 
in a dysfunction of mitochondria, and that it was the mitochondria present in the cytoplasmic 
extracts that corrected the deficiency. 
This approach was resumed in the United Kingdom to the point that a therapeutic project 
was submitted to the Human Fertilisation and Embryology Authority, debated, and approved. 
Opponents underlined that, using the protocol, this would be the first time a genetic change 
had been deliberately made to the human germ line (16).  
The prospect of deriving sperm cells and eggs from stem cells was also considered to be 
achievable in the near future (17). This opened the door to the application of the strategy for 
knocking out genes in animals to genetic modification of the human germ line. 
So, in a few years parallel and independent research lines converged, demonstrating the 
possibility of genetically modifying the human germ line.  
Independently, various transgenesis experiments on animals showed that some of these 
modifications could lead to performance enhancement (18). One of the most emblematic 
examples was the enhancement of learning and memory obtained by a genetic modification of 
one receptor of neurotransmitters, the glutamate receptor (19).  
In fact, since the 1970s, the hopes expressed by Rollin Hotchkiss and Edward Tatum have 
never been completely put aside. In 1998, a meeting was organized at the University of 
California Los Angeles that recommended brushing aside legal obstacles preventing the 
modification of the human germ line (20). In 2001, Jonathan King described this issue, and 
the apparently unanimous opposition to these experiments, as ―biology‘s last taboo‖ (21).  
What might appear as an irreversible move towards modification of the human genome 
has over recent years had to contend with a growing number of arguments against going in 
this direction, or suggesting radically different directions to address the same issues.  
Some of these arguments are not new. As already argued by Thomas Morgan, some 
genetic disorders can be addressed using drugs. More recently, Arnold Munnich has strongly 
argued that it is far too restrictive to limit the fight against genetic diseases to gene therapy. 
Like many diseases, they could be controlled, or even cured, by well-chosen drugs, and he has 
afforded examples confirming the efficiency of these indirect strategies (22).  
The importance given to the study of epigenetic modifications suggests also that another 
road—modification of the environment—might be followed to attenuate the effects of gene 
dysfunction. 
Similarly, although it was supported by a very different spirit, the myth of the 
convergence of nanotechnology, biotechnology, information technology and cognitive science 
(NBIC) led to radically different ways of enhancing humans, by fitting them with electronic 
devices to replace the functions of deficient organs. The creation of artificial retinas is 
progressing rapidly and in a few years will offer new ways to counter the consequences of 
some genetic defects. 
Of the two objectives always sought by supporters of intervention in human reproduction 
– elimination of defects and enhancement of human abilities – the first may be reached, more 
simply and efficiently, by early diagnosis (before implantation or prenatally) and elimination 
of the affected embryos.  
For a policy of germline modification to be efficient, it would have to be applied to 
individuals in whom only one copy of the gene is mutated (heterozygotes). They do not suffer 
from disease in recessive genetic disorders, which are the most frequent. Therefore, gene 
editing would create a risk for these individuals, without any direct benefit for them. In 
addition, a significant proportion of genetic defects are not transmitted by the parents, but 
arise de novo at each generation. The hope to eradicate forever genetic defects in humans is 
an illusion. Whatever the strategy used, the efforts will have to be permanently reinitiated.  
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Probably the most significant blow to the vision of a new world in which genome editing 
would have a major place came from the transformations of evolutionary biology. The idea 
that humans are at the top of evolution and have the responsibility to prolong its action on 
themselves and on other organisms has totally disappeared from the writings of evolutionary 
biologists, and probably also, at least partially, from their thoughts. The idea that mutations 
are good or bad is simplistic: the effect of a mutation depends upon the environment. A 
mutation with a deleterious effect can afford a benefit in particular conditions: such is the case 
for the mutation responsible for sickle cell anaemia which prevents the development of the 
agent of malaria. It is difficult to predict the short-term effects of a genetic modification – it is 
often impossible to anticipate its side effects –  but it is even more difficult to foresee the 
long-term effects in future environmental conditions that are unknown. 
 
CONCLUSIONS 
There has been a progressive separation between the therapeutic projects of genome 
editing and the more ambitious projects of genetic enhancement. Some of the former, limited 
in their objectives, will probably be developed, such as the replacement of mitochondria. 
Many other issues will find another solution, consisting for instance in earlier and more 
efficient diagnosis of affected embryos and their elimination.  
The place of genetic modification in human enhancement will be limited. Genetic 
modifications to obtain ―superhuman athletes‖ are still discussed, at least as a possibility that 
some will try to exploit (24), but it is obvious that this will be a modification of somatic cells 
in individuals, not of the germ cells. There is no longer any ambition to produce a ―race of 
athletes‖. 
Genetic modification of the germ line would require a consensus on the biological future 
of mankind that does not exist! A bigger brain is an objective that is no longer considered 
valuable. And what was sought through the creation of a bigger brain could be achieved by 
increased interconnection between the human body and electronic devices. 
Priorities have changed dramatically since the time when human beings were seen as the 
masters of evolution. Today, our aim is far less ambitious: to ensure the survival of humans 
and other species endangered by the uncontrolled human actions of previous centuries! 
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